EA200400253A1 - Применение соединения bibn4096bs в комбинации с другими лекарственными веществами против мигрени для лечения мигрени - Google Patents

Применение соединения bibn4096bs в комбинации с другими лекарственными веществами против мигрени для лечения мигрени

Info

Publication number
EA200400253A1
EA200400253A1 EA200400253A EA200400253A EA200400253A1 EA 200400253 A1 EA200400253 A1 EA 200400253A1 EA 200400253 A EA200400253 A EA 200400253A EA 200400253 A EA200400253 A EA 200400253A EA 200400253 A1 EA200400253 A1 EA 200400253A1
Authority
EA
Eurasian Patent Office
Prior art keywords
application
bibn4096bs
compound
migraine
migrain
Prior art date
Application number
EA200400253A
Other languages
English (en)
Russian (ru)
Inventor
Хенри Додс
Клаус Рудольф
Вольфганг Эберлайн
Original Assignee
Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг filed Critical Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг
Publication of EA200400253A1 publication Critical patent/EA200400253A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/48Ergoline derivatives, e.g. lysergic acid, ergotamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EA200400253A 2001-08-17 2002-08-10 Применение соединения bibn4096bs в комбинации с другими лекарственными веществами против мигрени для лечения мигрени EA200400253A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10139410A DE10139410A1 (de) 2001-08-17 2001-08-17 Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
PCT/EP2002/008993 WO2003015787A1 (en) 2001-08-17 2002-08-10 Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine

Publications (1)

Publication Number Publication Date
EA200400253A1 true EA200400253A1 (ru) 2004-08-26

Family

ID=7695082

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200400253A EA200400253A1 (ru) 2001-08-17 2002-08-10 Применение соединения bibn4096bs в комбинации с другими лекарственными веществами против мигрени для лечения мигрени

Country Status (22)

Country Link
EP (1) EP1420790B1 (enExample)
JP (1) JP2005503382A (enExample)
KR (1) KR20040027892A (enExample)
CN (1) CN1543347A (enExample)
AR (1) AR036265A1 (enExample)
AT (1) ATE304854T1 (enExample)
BR (1) BR0211970A (enExample)
CA (1) CA2454083A1 (enExample)
CO (1) CO5560577A2 (enExample)
DE (2) DE10139410A1 (enExample)
EA (1) EA200400253A1 (enExample)
EC (1) ECSP044979A (enExample)
ES (1) ES2250733T3 (enExample)
HR (1) HRP20040150A2 (enExample)
HU (1) HUP0401484A3 (enExample)
IL (1) IL159879A0 (enExample)
MX (1) MXPA04001364A (enExample)
NO (1) NO20041024D0 (enExample)
PL (1) PL365482A1 (enExample)
UY (1) UY27416A1 (enExample)
WO (1) WO2003015787A1 (enExample)
ZA (1) ZA200400313B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2313340C1 (ru) * 2006-02-20 2007-12-27 Дмитрий Владимирович Зимин Лекарственное средство, обладающее противомигренозным действием, и способ его изготовления
RU2424803C2 (ru) * 2008-04-07 2011-07-27 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН (НИИ фармакологии имени В.В.Закусова РАМН) Фармацевтическая композиция с противомигреневым действием (варианты)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465468B1 (en) 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
DE10207026A1 (de) * 2002-02-20 2003-08-28 Boehringer Ingelheim Kg Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung
EP1374870A1 (en) * 2002-06-24 2004-01-02 Rita Dobmeyer Medication for the treatment or prevention of migraine
DE10314617A1 (de) * 2003-04-01 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung des Hydrochlorids der Wirkstoffbase 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]-carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin in Kombination mit Sumatriptan zur Behandlung von Migräne
DE10338407A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Inhalationspulver enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin
DE10338403A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
DE10338402A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
DE10338399A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver
US20050065094A1 (en) 2003-09-05 2005-03-24 Boehringer Ingelheim International Gmbh Use of telmisartan for the prevention and treatment of vascular headache
CA2563687A1 (en) * 2004-04-20 2005-11-03 Boehringer Ingelheim International Gmbh Use of a cgrp-antagonist combined with a serotonin-reuptake inhibitor in order to treat migraines
EP1744784A2 (en) * 2004-05-11 2007-01-24 Becton, Dickinson and Company Formulations of anti-pain agents and methods of using the same
DE102004063753A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
CN102526031A (zh) * 2010-12-27 2012-07-04 湖南九典制药有限公司 一种鼻腔内使用的舒马普坦药物组合物及其制备方法
CN103385876B (zh) * 2012-05-08 2016-01-13 四川滇虹医药开发有限公司 一种夫罗曲坦的药物组合物及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU721035C (en) * 1996-09-10 2004-09-02 Dr. Karl Thomae Gmbh Modified aminoacids, pharmaceuticals containing these compounds and method for their production
DE19937304C2 (de) * 1999-08-10 2003-08-21 Boehringer Ingelheim Pharma Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2313340C1 (ru) * 2006-02-20 2007-12-27 Дмитрий Владимирович Зимин Лекарственное средство, обладающее противомигренозным действием, и способ его изготовления
RU2424803C2 (ru) * 2008-04-07 2011-07-27 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН (НИИ фармакологии имени В.В.Закусова РАМН) Фармацевтическая композиция с противомигреневым действием (варианты)

Also Published As

Publication number Publication date
EP1420790A1 (en) 2004-05-26
BR0211970A (pt) 2004-09-21
HUP0401484A2 (hu) 2004-12-28
DE60206289D1 (de) 2006-02-02
IL159879A0 (en) 2004-06-20
CN1543347A (zh) 2004-11-03
ATE304854T1 (de) 2005-10-15
HUP0401484A3 (en) 2007-03-28
NO20041024D0 (no) 2004-02-16
ZA200400313B (en) 2004-11-01
CA2454083A1 (en) 2003-02-27
CO5560577A2 (es) 2005-09-30
KR20040027892A (ko) 2004-04-01
AR036265A1 (es) 2004-08-25
MXPA04001364A (es) 2004-05-27
DE60206289T2 (de) 2006-06-08
DE10139410A1 (de) 2003-02-27
HRP20040150A2 (en) 2004-06-30
WO2003015787A1 (en) 2003-02-27
JP2005503382A (ja) 2005-02-03
ES2250733T3 (es) 2006-04-16
UY27416A1 (es) 2003-03-31
EP1420790B1 (en) 2005-09-21
ECSP044979A (es) 2004-04-28
PL365482A1 (en) 2005-01-10

Similar Documents

Publication Publication Date Title
RU93043528A (ru) Моногидрат 5-(2-(4-(1,2-бензотиазол-3-ил)-1-пиперазинил)этил)-6-хлор-1,3-дигидро-2н-индол-2-он хлоргидрата, способ его получения, фармацевтическая композиция, способ лечения
CR10114A (es) Composiciones farmacéuticas que comprenden inhibidoras de la hmg coa reductasa (divisional del exp. 6687)
MXPA04001364A (es) Uso de bibn4096 en combinacion con otros farmacos anti-migrana para el tratamiento de migrana, composicion y equipo.
BR0215157A (pt) Cis-2,4,5-trifenil-imidazolinas e seu uso no tratamento de tumores
DE69433802D1 (de) Therapeutisch wirksame linksdrehende und rechtsdrehende 1-((4-Chlorphenyl)phenylmethyl) Piperazine
RU2000100935A (ru) Производные ароил-пиперазина, их получение и их использование в качестве антагонистов тахикинина
WO2005056524A3 (en) Therapeutic agents useful for treating pain
AR011759A1 (es) Compuesto derivado de fenoximetilpiperidina, procedimientos para su preparacion, una composicion farmaceutica, el uso del mismo para la preparacion de un medicamento, para la preparacion de un producto intermedio, un solvato y un envase
SI1546127T1 (sl) Novi pirimidinamidni derivati in njihova uporaba
RU2008143703A (ru) ПРИМЕНЕНИЕ ИНГИБИТОРОВ c-Src В КОМБИНАЦИИ С ПИРИМИДИЛАМИНОБЕНЗАМИДОМ ДЛЯ ЛЕЧЕНИЯ ЛЕЙКОЗА
EE200100104A (et) 5-HT4 agonisti või antagonisti uus peroraalne ravimvorm
DK1458393T3 (da) Substituerede diketopiperaziner som oxytocinantagonister
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
BR9913982A (pt) Derivado de piridil-4h-1,2,4-oxadiazina opticamente ativo e seu uso no tratamento de doenças vasculares
NZ535611A (en) Pharmaceutical composition of a PDE4 or a PDE3/4 inhibitor and a histamine receptor antagonist
BR0211358A (pt) Uso do composto de 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-croman o e seus sais fisiologicamente aceitáveis
NO20043377L (no) R-(-)-1-[2-(7-klorbenzo[b]tiofen-3-yl-metoksy)-2-(2,4-diklorfenyl)-etyl]-1H-imidazol
TW200501956A (en) Use of the hydrochloride of the compound 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]-carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine in combination with sumatriptan for the treatment of migraine
WO2002055022A3 (en) Active metabolite of antifungal compound
WO2001068063A3 (en) Novel use of (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
ATE431147T1 (de) Mittel zur behandlung des integrationsdysfunktionssyndroms
WO2001079195A3 (en) Pyridine and pyrazine derivatives as thrombin inhibitors
WO2006094640A3 (en) Roflumilast and integrin inhibitor combination and method of treatment
EA200401010A1 (ru) Порошковое средство для ингаляции, содержащее cgrp-антагонист bibn4096, и способ его получения
NO20033634L (no) GLyT-1-inhibitorer